Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity.
about
Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205Antibody promiscuity: Understanding the paradigm shift in antigen recognitionCrystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvComplex of a Protective Antibody with Its Ebola Virus GP Peptide Epitope: Unusual Features of a Vλx Light ChainStructure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 NeutralizationStructure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data setStructural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based ImmunogensCrystal Structure of the HIV-2 Neutralizing Fab Fragment 7C8 with High Specificity to the V3 Region of gp125Structural Analysis of Human and Macaque mAbs 2909 and 2.5B: Implications for the Configuration of the Quaternary Neutralizing Epitope of HIV-1 gp120Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic StructureRabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected HumansThermodynamic Signatures of the Antigen Binding Site of mAb 447–52D Targeting the Third Variable Region of HIV-1 gp120Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc ComplexRole of κ→λ light-chain constant-domain switch in the structure and functionality of A17 reactibodyTwo HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entryHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesIndirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjectsAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesMax Bergmann lecture protein epitope mimetics in the age of structural vaccinologyAn Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.Appreciating HIV type 1 diversity: subtype differences in Env.Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies.Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesA strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoproteinWorldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.HIV-1 envelope glycoprotein variable loops are indispensable for envelope structural integrity and virus entry.Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesComputational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodiesStructure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designIdentification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccinationAntibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response.
P2860
Q24681004-F9A85565-4D0C-4833-90AC-C2EFDEC13DA9Q26801316-64705B12-409D-4B39-8B30-39038BB74CDBQ27644383-1E3DA241-6A56-4ADD-9F95-008F3918FF75Q27649064-B6A48F3B-5529-4CC0-BE03-D46228CE98AFQ27649247-8A71F826-A8CD-4799-8ED8-27B1C07E9B58Q27650903-2593C3B0-EC86-45BC-B74C-8639A33D8A58Q27658173-674A759B-BB90-4587-9032-F5288E01FBBEQ27667679-88B6C505-54E0-41B7-B1BF-85AA6848395CQ27667819-A2634248-267C-4957-BA81-2DE07963DCFEQ27676155-A6DCD80A-7553-4796-8EB9-940F05F16987Q27679123-5E052AB8-1AB9-4E19-B592-2794DDC0E0D2Q27679559-9FDDF062-B05D-4998-B0C4-5CA47517E87EQ27679932-18FA42BA-A1C6-4277-89A5-6A99378452C4Q27681993-F026E627-ADC0-4B0F-A6B2-06A3EB32EC77Q28475912-8649BE48-5E2D-4813-A1E3-A072088D1AC3Q28602877-3F69C9B1-DF87-4500-A7FB-F88B026077E3Q28743129-B940CDB8-8E00-4375-A7ED-69F1831905CDQ28752503-FCFF442F-31B7-4DFA-B8B0-BF1A72981F3AQ30155145-3F9CFC8B-7AC0-4B89-9AAF-2A2F23FA6F82Q30375785-1C011FC3-1816-4824-AE9C-E72FAFD9C477Q30375834-082E69AF-9097-4ADF-9257-F567C853EB16Q30416200-3373AC64-5693-41CB-AB90-F3DFB78A14E0Q30994182-5A8BDB48-FCB1-4074-AFB4-E772780135B3Q33522232-3DA25C7D-2361-4F9D-814B-50C860120761Q33786222-669DD6E2-E281-4E37-8357-81366BD5DE4FQ33820645-EFAED5CC-9062-4D93-8C14-11D2E506BB93Q34085098-1D809D89-6862-4C19-A47B-1C702A6508C8Q34100194-2B060883-8EA6-406B-8804-7ED5B6E8E803Q34128200-C4B1F198-F09F-48D6-B789-58F06EE5FC48Q34204047-861562D1-423E-450C-87CE-DD962B88F5A4Q34847834-A0F2563D-8E85-4B34-B245-71CD31D2E97BQ34924647-FB81AAE8-99DD-482D-9AC2-8EAE9883AD09Q34948847-0B571AB3-D038-421E-9BB6-F45B06381A07Q35108505-E442BEF0-C930-4EFE-9FEE-395A22A5FDF4Q35196671-35CEA7DC-89E3-46CF-A712-9EC27FE2BAE9Q35857404-33931770-4D31-4E1E-8EA7-9871B332A937Q36384117-AFEC50E7-1276-4F78-853B-F91C90BFC4EEQ36424523-AADE943C-2E60-423D-AE8D-A30F9728689BQ36804634-7697B234-753D-4AE3-BA92-F7CE6D11133EQ36823297-C6349994-3755-4415-B413-2C58A279FC5E
P2860
Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Crystal structures of human im ...... de for HIV-1 cross-reactivity.
@en
Crystal structures of human immunodeficiency virus type 1
@nl
type
label
Crystal structures of human im ...... de for HIV-1 cross-reactivity.
@en
Crystal structures of human immunodeficiency virus type 1
@nl
prefLabel
Crystal structures of human im ...... de for HIV-1 cross-reactivity.
@en
Crystal structures of human immunodeficiency virus type 1
@nl
P2860
P356
P1433
P1476
Crystal structures of human im ...... de for HIV-1 cross-reactivity.
@en
P2093
Robyn L Stanfield
Susan Zolla-Pazner
P2860
P304
P356
10.1128/JVI.00205-06
P407
P577
2006-06-01T00:00:00Z